Group letter re: DEA’s proposed rule on controlled substances quotas

May 4, 2018

RE: Controlled Substances Quotas [Docket No. DEA-480]

The undersigned groups thank the Drug Enforcement Administration (DEA) for the opportunity to comment on its proposed rule regarding controlled substances quotas. Although we support DEA’s efforts to combat diversion, we are concerned that the proposed rule is focused on diversion to the exclusion of another critical factor – drug shortages. To ensure that legitimate medical needs are met, it is imperative that drug shortages be considered as aggregate production quotas (APQ) are set and adjusted.


Read the full letter below.

Related Resources

Special Bulletin
Member
The Centers for Medicare…
Advisory
Member
The Centers for Medicare…
Advisory
Member
The AHA released a detailed summary of the Centers for Medicare…
Special Bulletin
Member
The Department of Health and Human Services (HHS) Office for Civil Rights May 2 issued a final rule concerning federal health care-related conscience…
Letter/Comment
Public
AHA letter to Representative Brad Schneider expressing support for legislation, H.R. 2439, the Opioid Workforce Act of 2019,
Advisory
Member
On Oct. 24, 2018, President Trump signed into law the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and…